A Systematic Review of the Efficacy of Chemotherapy and Immunotherapy Alone Versus Chemotherapy Combined With Immunotherapy for Biliary Tract Cancer DOI Creative Commons

Gift Andrew Sabola

Research Square (Research Square), Journal Year: 2023, Volume and Issue: unknown

Published: June 28, 2023

Abstract Background : Biliary tract cancer (BTC) remains one of the rare but most devastating diseases, with a rising global burden. The increasing mortality and morbidity trends have indicated need for improved interventions effective treatment all BTC subtypes. Henc, there has been proposals use combined chemotherapy immunotherapy. Methods Results main research question was “How is Chemotherapy-Immunotherapy combination compared to Chemotherapy Immunotherapy alone in treating Tract Cancer?” systematic review followed mixed-method design based on PRISMA guidelines. This focused studies published between 2022 2023. results showed that both immunotherapy monotherapies are BTC. Conclusions as well safer.

Language: Английский

Nuclear-Targeting Lipid PtIV Prodrug Amphiphile Cooperates with siRNA for Enhanced Cancer Immunochemotherapy by Amplifying Pt-DNA Adducts and Reducing Phosphatidylserine Exposure DOI
Dengshuai Wei, Junning Fan, Jianqin Yan

et al.

Journal of the American Chemical Society, Journal Year: 2023, Volume and Issue: 146(1), P. 1185 - 1195

Published: Dec. 27, 2023

Patients treated with Pt-based anticancer drugs (Pt

Language: Английский

Citations

39
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma DOI Creative Commons
Xu Yang,

Baofeng Lian,

Nan Zhang

et al.

BMC Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: Jan. 29, 2024

Abstract Background Microsatellite instability-high (MSI-H) is a unique genomic status in many cancers. However, its role the features and immunotherapy cholangiocarcinoma (CCA) unclear. This study aimed to systematically investigate characterization efficacy of MSI-H patients with CCA. Methods We enrolled 887 CCA this study. Tumor samples were collected for next-generation sequencing. Differences alterations between microsatellite stability (MSS) groups analyzed. also investigated survival PD-1 inhibitor-based two 139 advanced Results Differential genetic MSS included mutations ARID1A , ACVR2A TGFBR2 KMT2D RNF43 PBRM1 which enriched groups. Patients an have significantly higher tumor mutation burden (TMB) (median 41.7 vs. 3.1 muts/Mb, P < 0.001) more positive programmed death ligand 1 (PD-L1) expression (37.5% 11.9%, than those status. Among receiving therapy, had longer median overall (OS, hazard ratio (HR) = 0.17, progression-free (PFS, HR 0.14, MSS. Integrating PD-L1 (combined score ≥ 5) could distinguish immunotherapy. Conclusions was associated TMB value tumors. Moreover, who received immunotherapy, improved both OS PFS. Trial registration registered on ClinicalTrials.gov 07/01/2017 (NCT03892577).

Language: Английский

Citations

14
Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma DOI Creative Commons
YeXing Huang, ZeFeng Du, Anna Kan

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Feb. 7, 2024

Background Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive cancer with dismal prognosis and few effective therapeutic approaches. This study aimed to investigate the efficacy, safety, predictive biomarkers of hepatic arterial infusion chemotherapy (FOLFOX-HAIC) in combination lenvatinib PD-1 inhibitor for patients advanced iCCA. Methods Locally or metastatic iCCA receiving triple therapy lenvatinib, inhibitor, FOLFOX-HAIC were included this retrospective study. Primary endpoint was progression-free survival, evaluated using RECIST criterion. The secondary endpoints overall objective response rate, safety. Whole exome RNA sequencing tumor biopsy tissues performed biomarker exploration. Results Between May, 2019 December 2022, total 46 primary showed median survival 9.40 months (95% CI: 5.28-13.52), 6-month rate 76.1%. 16.77 CI, 14.20-19.33), an 47.8% disease control 91.3% per RECIST. In addition, 4.3% 8.7% achieved complete all lesions intrahepatic target mRECIST, respectively. most common treatment-related adverse events neutropenia, thrombocytopenia, elevated aspartate aminotransferase alanine level. Furthermore, integrated analysis genetic, transcriptomic, immunohistochemistry data revealed that pre-existing immunity (high expression level immune-related signatures intra-tumoral CD8 + T cell density) baseline associated superior clinical benefits. However, evaluation mutation burden did not show potential value combination. Conclusion demonstrated promising antitumor activity manageable safety profiles Moreover, our also new perspectives on efficacy.

Language: Английский

Citations

6
Immune repertoire sequencing reveals differences in treatment response to camrelizumab plus platinum-based chemotherapy in advanced ESCC DOI Creative Commons
Xiaoling Zhang,

Wenqi Zhao,

Yunyi Du

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 26, 2025

This study evaluated the efficacy and safety of camrelizumab combined with platinum-based chemotherapy (taxanes [T] or fluorouracil agents [F] plus platinum [P] drugs) as first-line treatment in advanced esophageal squamous cell carcinoma (ESCC), using immune repertoire sequencing (IRS) to explore response mechanism. In this multi-center, prospective cohort study, 88 patients received TP FP, achieving a 1-year progression-free survival 56.8% overall 68.2%. The objective rate (ORR) was 64.8%, disease control 91.1%. While most treatment-related adverse events were mild, 12.5% experienced grade ≥3 toxicities. IRS showed significant differences T-cell receptor (TCR) β-chain immunoglobulin heavy chain between (ORR group) without ORR (non-ORR group), particularly distribution expression some genes. Specifically, we found amino acid composition complementarity determining region 3 (CDR3) polypeptide sequences TCR B-cell (BCR) non-ORR groups. For TCR, observed substantial oligoclonal enrichment abundance specific V J Similarly, for BCR, detected clonotype CDR3 segments identified several differential Camrelizumab is effective well-tolerated ESCC, may reveal mechanism influencing response.

Language: Английский

Citations

0
Combined Chemotherapy-Immunotherapy for Advanced Biliary Tract Cancer (BTC): A Clinical, Genomic, and Biomarker Analysis DOI
Zhang Yon, Miaomiao Gou

Journal of Gastrointestinal Cancer, Journal Year: 2025, Volume and Issue: 56(1)

Published: April 1, 2025

Language: Английский

Citations

0
HBV infection effects prognosis and activates the immune response in intrahepatic cholangiocarcinoma DOI Creative Commons
Zhizhen Li, Qingxiang Gao, Yingjun Wu

et al.

Hepatology Communications, Journal Year: 2024, Volume and Issue: 8(1)

Published: Jan. 1, 2024

Background: The impact of HBV infection on the prognosis patients with intrahepatic cholangiocarcinoma (ICC) remains uncertain, and underlying mechanism has not been elucidated. This study aims to explore potential via clinical perspectives immune features. Methods: We retrospectively reviewed 1308 ICC treated surgically from January 2007 2015. Then, we compared immune-related markers using immunohistochemistry staining obtain gene expression profile GSE107943 related literature for preliminary bioinformatics analysis. Subsequently, conducted a drug sensitivity assay validate role TNFSF9 in organoid-autologous cell coculture system patient-derived organoids–based xenograft platform. Results: analysis revealed that tumors without exhibited greater size higher likelihood lymphatic metastasis, tumor invasion, relapse. After resection, HBV-infected had longer survival time than uninfected ( p <0.01). Interestingly, HBV-positive was percentage CD8 + T cells tissue <0.05). screened 21 differentially expressed genes investigated function through analyses. organoids lower infection. growth HBV-negative significantly inhibited by inhibiting neutralizing antibody. Additionally, rate faster HbsAg (−) model (+) group. Conclusions: activation response induced makes differ patients.

Language: Английский

Citations

4
Advancements in Stimulus-Responsive Co-Delivery Nanocarriers for Enhanced Cancer Immunotherapy DOI Creative Commons

Meng-Ru Zhang,

Linlin Fang, Yang Guo

et al.

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 3387 - 3404

Published: April 1, 2024

Abstract: Cancer immunotherapy has emerged as a novel therapeutic approach against tumors, with immune checkpoint inhibitors (ICIs) making significant clinical practice. The traditional ICIs, PD-1 and PD-L1, augment the cytotoxic function of T cells through inhibition tumor evasion pathways, ultimately leading to initiation an antitumor response. However, implementation ICIs encounters obstacles stemming from existence immunosuppressive microenvironment inadequate infiltration CD8 + cells. Considerable attention been directed towards advancing immunogenic cell death (ICD) potential solution counteract microenvironment. This holds promise in transforming "cold" tumors into "hot" that exhibit responsiveness antitumor. By combining ICD synergistic response can be achieved. combination inducers PD-1/PD-L1 is hindered by issues such poor targeting uncontrolled drug release. An advantageous presented stimulus-responsive nanocarrier integrating physicochemical properties inhibitors, facilitating precise delivery specific tissues for optimal therapy. Moreover, these nanocarriers leverage distinct features accomplish controlled release regulate kinetics delivery. article aims investigate advancement co-delivery utilizing inhibitors. Special focus dedicated exploring advantages recent advancements this system enabling inducers. molecular mechanisms are concisely summarized. In conclusion, we examine research prospects challenges could greatly enhance immunotherapeutic approaches cancer treatment. Keywords: therapy, death, co-delivery, immune-checkpoint

Language: Английский

Citations

4
Gamma Knife Stereotactic radiotherapy combined with tislelizumab as later-line therapy in pMMR/MSS/MSI-L metastatic colorectal cancer: A Phase II Trial Analysis DOI Open Access
Yiran Zhang,

Hanyang Guan,

Shijin Liu

et al.

Published: Jan. 21, 2025

An immunosuppressive tumor microenvironment limits the efficacy of immunotherapy, thus patients with MSS and pMMR mCRC often face great challenges.In this phase II trial, received Gamma Knife SBRT combined Tislelizumab. P Biomarker analysis was performed pre- post-treatment. From November 2022 to July 2024, 13 20 achieved PR, 6 SD. mPFS 10.7 months (95% CI, 6.4-15.0). With no grade 4 events noted, common adverse included nausea (65%), anemia (55%), fatigue (45%). For who had not responded first second-line therapies, combo tislelizumab showed high reasonable safety. Significant post-radiotherapy improvements in tumor’s microenvironment. These results imply that pMMR/MSS/MSI-L were unresponsive chemotherapy, provides a safe powerful later-line treatment alternative.

Language: Английский

Citations

0
Gamma Knife Stereotactic radiotherapy combined with tislelizumab as later-line therapy in pMMR/MSS/MSI-L metastatic colorectal cancer: A Phase II Trial Analysis DOI Open Access
Yiran Zhang,

Hanyang Guan,

Shijin Liu

et al.

Published: Jan. 21, 2025

An immunosuppressive tumor microenvironment limits the efficacy of immunotherapy, thus patients with MSS and pMMR mCRC often face great challenges.In this phase II trial, received Gamma Knife SBRT combined Tislelizumab. P Biomarker analysis was performed pre- post-treatment. From November 2022 to July 2024, 13 20 achieved PR, 6 SD. mPFS 10.7 months (95% CI, 6.4-15.0). With no grade 4 events noted, common adverse included nausea (65%), anemia (55%), fatigue (45%). For who had not responded first second-line therapies, combo tislelizumab showed high reasonable safety. Significant post-radiotherapy improvements in tumor’s microenvironment. These results imply that pMMR/MSS/MSI-L were unresponsive chemotherapy, provides a safe powerful later-line treatment alternative.

Language: Английский

Citations

0
Efficacy and safety of immune checkpoint inhibitors in advanced biliary tract cancer: a real-world study DOI Creative Commons
Yichen Zheng,

Jiamin Guo,

Tianhui Ren

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 31, 2025

Background Immune checkpoint inhibitors (ICIs) combined with gemcitabine and cisplatin chemotherapy have become the standard first-line treatment for advanced biliary tract cancer (BTC). However, real-world evidence on domestic ICIs widely used in China therapeutic outcomes across lines remains limited. This study aimed to assess effectiveness safety profiles of BTC patients, while concurrently elucidating potential efficacy variations among distinct ICI subtypes. Methods We analyzed patients unresectable, locally advanced, or metastatic treated at West Hospital (January 2019–October 2023). Primary endpoint was overall survival (OS), secondary endpoints included progression-free (PFS), objective response rate (ORR), disease control (DCR), safety. Kaplan-Meier curves, propensity score matching (PSM), Cox proportional hazards regression efficacy. Results A total 221 were enrolled. Among them, 137 received first line, 84 second later lines. For as therapy, median OS 15.7 months (95% CI: 13.1-19.8) PFS 8.4 7.6-10.3). In contrast, had shorter 9.8 8.1–12.3) 5.6 4.2–6.8). The reduced later-line treatments may reflect prior resistance generally poorer patient conditions compared recipients. 211 (95.5%) experienced least one adverse event (AE), 93 (42.1%) them grade 3 higher AEs. incidence immune-related events (irAEs) 35.8%, 8.6% experiencing 3-4 irAEs. most common are Durvalumab Sintilimab, which we interested comparing. showed numerically superior vs Sintilimab (19.3 10.2 months, p&lt;0.001) unmatched analysis, though significance attenuated after PSM (16.1 13.1 p=0.299). Conclusion demonstrate robust manageable toxicity settings, supporting their use both first- BTC. whether alternatives remain viable options warranting further validation.

Language: Английский

Citations

0